Trials / Completed
CompletedNCT06064526
An Observational, Retrospective Multicentre Medical Record Review to Describe the Post-authorisation Early Clinical Experience of Dupilumab in the Treatment of Adult Severe Asthma
Real-world Experience of Dupilumab for the Treatment of Severe Asthma in the United Kingdom: a Retrospective Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 144 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this retrospective medical record review is to describe the real-world clinical effectiveness of dupilumab with patients in the United Kingdom with severe asthma.
Detailed description
Participants initiating treatment with dupilumab in the UK between 5th July 2019 and 12th August 2021 will be included in the study record review, permitting participation in research and if medical records are available for review. No intervention will be administered in this clinical trial. Data will be collected from hospital medical records and other hospital databases.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No intervention | Non-interventional study based on secondary use of hospital medical records |
Timeline
- Start date
- 2023-04-19
- Primary completion
- 2024-10-15
- Completion
- 2024-10-15
- First posted
- 2023-10-03
- Last updated
- 2024-11-14
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT06064526. Inclusion in this directory is not an endorsement.